📰 Combination Study News
Combination Study News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Combination Study. Real-time updates on events, politics, business and more.
January 23, 2024
2023 Fourth-Quarter reported sales growth of 7.3% to $21.4 Billion with operational growth of 7.2%* and adjusted operational growth of 5.7%*. Operational growth excluding COVID-19 Vaccine of...
August 31, 2023
Operator: Ladies and gentlemen, thank you for standing by. Welcome to the BioLineRx Second Quarter 2023 Financial Results Conference Call. All participants are presently in listen-only mode.
May 25, 2023
Operator: Ladies and gentlemen, thank you for standing by. Welcome to the BioLineRx First Quarter 2023 Financial Results Conference Call.
August 4, 2022
04.08.2022 - – Phase 3 DeFi Trial Evaluating Nirogacestat in Adult Patients with Progressing Desmoid Tumors Met Its Primary and All Key Secondary Endpoints – – Encouraging Preliminary Data from Phase 1/2 Study Evaluating Nirogacestat in Combination with ...
June 8, 2022
Investegate announcements from Faron Pharma. Oy, First Patient Dosed in Ph I/II BEXMAB Combo Study
May 16, 2022
Faron Pharmaceuticals Ltd. ("Faron" or "Company") Faron Announces US Food and Drug Administration and Finnish Medicines Agency Approval to Initiate Phase I/II...
May 16, 2022
Investegate announcements from Faron Pharma. Oy, FDA and FIMEA approve BEXMAB study to begin
December 16, 2020
Search jobs Precigen Provides Latest Clinical Developments at Virtual R&D Update Event GERMANTOWN, Md., Dec. 15, 2020 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today held an R&D virtual event to provide an update on the latest progress for its clinical pipeline. The event showcased data from several of Precigens most advanced clinica...